加载中...

MedXY News - breast cancer

MedXY AI/MedXY News/Tag: breast cancer

MedXY News

EnglishTag

breast cancer

61 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg

Section: Clinical UpdatesOct 9, 2025

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone thera

Section: Clinical Updates

Oct 7, 2025

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial

The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial st

Section: CardiologyOct 7, 2025

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence

A phase 2 randomized trial demonstrates that targeting dormant disseminated tumor cells with hydroxychloroquine and everolimus is safe, feasible, and reduces minimal residual disease, potentially improving recurrence-free survival in breast

Section: newsOct 7, 2025

Understanding Breast Cancer Risk: Habits and Genetic Factors That Quietly Increase Danger

Understanding Breast Cancer Risk: Habits and Genetic Factors That Quietly Increase Danger

Breast cancer is the most common cancer among women, with 90% of patients belonging to high-risk groups. This article explores five major risk factors, early detection strategies, and lifestyle changes crucial for prevention.

Section: Family Medicine & NutritionOct 5, 2025

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

Section: OB/GYN & Women's HealthOct 5, 2025

Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies

Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies

A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especial

Section: newsOct 5, 2025

Extending Endocrine Treatment Duration for Early Breast Cancer

Extending Endocrine Treatment Duration for Early Breast Cancer

This article reviews a patient-level meta-analysis on prolonging endocrine therapy for early breast cancer in postmenopausal women, focusing on the benefits of additional aromatase inhibitor treatment after five years of initial therapy.

Section: newsOct 5, 2025

Advancing Breast Cancer Detection: AI Identifies Missed Interval Cancers on Mammograms

Advancing Breast Cancer Detection: AI Identifies Missed Interval Cancers on Mammograms

A recent study shows that an AI system can detect interval breast cancers missed by radiologists on mammograms, potentially improving early diagnosis and screening outcomes in women with dense breasts.

Section: AIOct 4, 2025

Breast Nodules: How Close Are They to Breast Cancer?

Breast Nodules: How Close Are They to Breast Cancer?

This article explores the relationship between breast nodules and breast cancer, addressing common concerns and offering actionable health insights.

Section: newsOct 2, 2025

First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance

First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance

Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profil

Section: Clinical UpdatesOct 2, 2025

Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications

Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications

Vepdegestrant, an oral PROTAC estrogen receptor degrader, significantly prolongs progression-free survival compared to fulvestrant in ESR1-mutant advanced breast cancer, but not in the overall ER+/HER2– population.

Section: Clinical UpdatesOct 2, 2025

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial

The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.

Section: Clinical UpdatesOct 2, 2025

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and

Section: Clinical UpdatesOct 1, 2025

One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth

One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth

A single session of resistance or high-intensity interval training boosts anti-cancer myokines in breast cancer survivors, significantly suppressing cancer cell growth in vitro.

Section: Family Medicine & NutritionOct 1, 2025

Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial

Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial

Adding 5 mg olanzapine after anthracycline-based chemotherapy significantly improves nausea and vomiting control with minimal sedation in breast cancer patients compared to standard antiemetic therapy alone.

Section: Clinical UpdatesOct 1, 2025

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Section: Clinical UpdatesOct 1, 2025

Inconsistent Bone Health Management in Older Women With Breast Cancer: Insights From the Age Gap Study

Inconsistent Bone Health Management in Older Women With Breast Cancer: Insights From the Age Gap Study

Significant variation exists in bone health management for older women receiving endocrine therapy for breast cancer, highlighting the need for standardized care.

Section: Clinical UpdatesOct 1, 2025

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies

Antibody-drug conjugates (ADCs) have transformed breast cancer therapy but bring notable toxicity risks. This review examines the clinical evidence, adverse event management, and future directions for optimizing ADC use.

Section: Clinical UpdatesSep 30, 2025

Removing Out-of-Pocket Costs Increases Access to 3D Mammograms

Removing Out-of-Pocket Costs Increases Access to 3D Mammograms

Eliminating a $45 fee for advanced breast cancer screening technology improves access and reduces health disparities, according to recent research.

Section: newsSep 30, 2025

Prev 1 2 3 4 Next